
## **Treatment Challenges Addressed**

# Is Drug-drug Interaction, A Challenge in Treating Comorbid Condition like Anxiety with BPD?

omorbidity is the rule, and not the exception in bipolar disorder (BPD).¹ Naturally, successful management of BPD would also warrant timely diagnosis and management of the comorbid conditions. Of the various comorbidities reported for BPD, anxiety disorders are one of the commonest. Multiple anxiety disorders exist as comorbidities in more than 1/3rd of patients with BPD.²

# Anxiety: A Commonest Comorbidity of BPD<sup>3,4</sup>




#### **Treatment Challenges**

Presence of anxiety and bipolar disorders as co-morbidity aggravates the symptoms of both the disease and have poor prognosis and have frequent remission impacting the overall quality of life of patients. The management of these patients also becomes more challenging due to overlapping adverse events and drug -drug interactions.<sup>2</sup>

## Drug Interaction with Other Psychotropic Drugs used in Anxiety

- Drug-drug interaction studies and pharmacokinetic studies for co-administration of divalproex with other psychotropic medication has shown minor to moderate drug interactions.5,6
- Divalproex does not result in severe interaction with contraindications making its co-administration with anti-anxiety drugs safe with acceptable safety profile.

Drug interactions of Divaproex Sodium and some commonly used Psychotropic drugs used in anxiety<sup>7,8</sup>



- ~ Possible interaction\*
- + Additive effect
- X Not recommended
- ? Interaction unknown

Severe interaction

Minor-to-moderate interaction

The drug interactions between drugs are represented by the color and the symbol in the column with the drug present in the horizontal line. For e.g.: Divalproex have minor to moderate [Blue color] possible interaction (~) with escitalopram, similarly escitalopram can have minor to moderate [Blue color in column] additive effect (+) with Diazepam.

\*Observe precaution & monitor the patients

References: 1. McEiroy St. *J Clin Psychiatry*. 2004;65 Suppl 15:35–44. 2. Spoorthy MS, Chakrabarti S, Grover S. Comorbidity of bipolar and anxiety disorders: An overview of trends in research. *World J Psychiatry*. 2019 Jan 4;9(1):7–29. 3. Hitty DM, Leamon MH, Lim RF, Kelly RH, Hales RE. A review of bipolar disorder in adults. *Psychiatry* (*Edgmont*). 2006;3(9):43–55. 4. McEiroy St. Diagnosing and treating comorbid (complicated) bipolar disorder. *The Journal of clinical psychiatry*. 2004;65:35–44. 5. Remmerie B, Ariyawansa J, De Meulder M et al. Drug-drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders. *The Journal of Clinical Pharmacology*. 2016 Jun;56(6):683–92. 6. Winter HR, DeVane CL, Figueroa C, et al. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine furnarate and divalproex sodium in patients with schizophrenia, schizo- affective disorder, or bipolar disorder. *Human Psychopharmacology: Clinical and Experimental*. 2007 Oct;22(7):469–76. 7. https://www.pdr.net/ (Accessed on 05/10/2020) 8. https://www.drugs.com/ interaction/ (Accessed on 10/10/2020).

Disclaimer: The matter published herein has been developed by clinicians and medical writers. It has also been validated by experts. Although great care has been taken in compiling and checking the information, the authors, shall not be responsible or in anyway, liable for any errors, omissions or inaccuracies in this publication whether arising from negligence or otherwise however, or for any consequences arising there from. The inclusion or exclusion of any product does not mean that the publisher advocates or rejects its use either generally or in any particular field or fields.



#### Dear Doctor,

On the basis of your clinical experience of managing BPD & co-morbidities, which are the agents for which you would like to know more about their actual or potential interactions.

